Provectus Biopharmaceuticals’ PV-10 Data to Feature in Poster Presentation by Moffitt Cancer Center at the American Society...
April 02 2014 - 6:00AM
Business Wire
McCormick Place in Chicago, IL, May 30-June
3, 2014
Provectus Biopharmaceuticals, Inc. (OTCQB:PVCT)
(http://www.pvct.com), a development-stage oncology and dermatology
biopharmaceutical company, announced today that data on its
investigational drug PV-10 will be featured in a presentation by
investigators from Moffitt Cancer Center in a Poster Highlights
Session of the American Society of Clinical Oncology (ASCO) Annual
Meeting at McCormick Place, Chicago, IL, May 30-June 3, 2014. The
time and date of the presentation are expected to become available
on the ASCO website, http://am.asco.org, on April 21, 2014.
The poster, based upon abstract #9028, is entitled "Assessment
of immune and clinical efficacy after intralesional PV-10 in
injected and uninjected metastatic melanoma lesions," and is
authored by Amod Sarnaik, MD and colleagues of Moffitt.
Craig Dees, PhD, CEO of Provectus said, "We value our
relationship with Moffitt greatly, and we are excited by the
assessment Dr. Sarnaik has made on clinical and immunologic
activity of intralesional PV-10.”
Provectus has recently submitted an application to the FDA for
breakthrough therapy designation for PV-10 based on the results
from its Phase 2 clinical study of melanoma and is researching its
efficacy for other indications.
About Moffitt Cancer Center
Located in Tampa, Moffitt is one of only 41 National Cancer
Institute-designated Comprehensive Cancer Centers, a distinction
that recognizes Moffitt’s excellence in research, its contributions
to clinical trials, prevention and cancer control. Moffitt is the
No. 1 cancer hospital in Florida and has been listed in U.S. News
& World Report as one of “America’s Best Hospitals” for cancer
since 1999. For more information, visit MOFFITT.org, and follow the
Moffitt momentum on Facebook, Twitter and YouTube.
About Provectus Biopharmaceuticals, Inc.
Provectus Biopharmaceuticals specializes in developing oncology
and dermatology therapies. Its novel oncology drug PV-10 is
designed to selectively target and destroy cancer cells without
harming surrounding healthy tissue, significantly reducing
potential for systemic side effects. Its oncology focus is on
melanoma, breast cancer and cancers of the liver. The Company has
received orphan drug designations from the FDA for its melanoma and
hepatocellular carcinoma indications. Its dermatological drug PH-10
also targets abnormal or diseased cells, with the current focus on
psoriasis and atopic dermatitis. Provectus has recently completed
Phase 2 trials of PV-10 as a therapy for metastatic melanoma, and
of PH-10 as a topical treatment for atopic dermatitis and
psoriasis. Information about these and the Company's other clinical
trials can be found at the NIH registry, www.clinicaltrials.gov.
For additional information about Provectus please visit the
Company's website at www.pvct.com or contact Porter, LeVay &
Rose, Inc.
FORWARD-LOOKING STATEMENTS: The forward-looking statements
contained herein are subject to certain risks and uncertainties
that could cause actual results to differ materially from those
reflected in the forward-looking statements. Readers are cautioned
not to place undue reliance on these forward-looking statements,
which reflect management's analysis only as of the date hereof. The
company undertakes no obligation to publicly revise these
forward-looking statements to reflect events or circumstances that
arise after the date thereof.
Provectus Biopharmaceuticals, Inc.Peter R. Culpepper, CFO,
COO866-594-5999 #30orPorter, LeVay & Rose, Inc.Marlon Nurse,
DM, SVP – Investor Relations212-564-4700orBill Gordon – Media
Relations212-724-6312
Provectus Biopharmaceuti... (QB) (USOTC:PVCT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Provectus Biopharmaceuti... (QB) (USOTC:PVCT)
Historical Stock Chart
From Sep 2023 to Sep 2024